tetano
Editor, Senior Moderator
Diabetes Obes Metab
. 2020 Dec 15.
doi: 10.1111/dom.14296. Online ahead of print.
Effects of Dapagliflozin on Prevention of Major Clinical Events and Recovery in Patients with Respiratory Failure due to COVID-19: The Design and Rationale for the DARE-19 study
Mikhail Kosiborod[SUP] 1 2 [/SUP], Otavio Berwanger[SUP] 3 [/SUP], Gary G Koch[SUP] 4 [/SUP], Felipe Martinez[SUP] 5 [/SUP], Omar Mukhtar[SUP] 6 [/SUP], Subodh Verma[SUP] 7 8 9 [/SUP], Vijay Chopra[SUP] 10 [/SUP], Ali Javaheri[SUP] 11 [/SUP], Philip Ambery[SUP] 12 [/SUP], Samvel B Gasparyan[SUP] 12 [/SUP], Joan Buenconsejo[SUP] 13 [/SUP], C David Sj?str?m[SUP] 12 [/SUP], Anna Maria Langkilde[SUP] 12 [/SUP], Jan Oscarsson[SUP] 12 [/SUP], Russell Esterline[SUP] 13 [/SUP]
Affiliations
Abstract
Aims: Coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated morbidity and mortality, particularly in patients with underlying metabolic, cardiovascular, respiratory, or kidney disease. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has shown significant cardio- and renoprotective benefits in patients with type 2 diabetes (with and without atherosclerotic cardiovascular disease), heart failure, and chronic kidney disease, and may provide similar organ protection in high-risk patients with COVID-19.
Materials and methods: DARE-19 (NCT04350593) is an investigator-initiated, collaborative, international, multicenter, randomized, double-blind, placebo-controlled study testing the dual hypotheses that dapagliflozin can reduce the incidence of cardiovascular, kidney and/or respiratory complications or all-cause mortality, or improve clinical recovery, in adult patients hospitalized with COVID-19 but not critically ill on admission. Eligible patients will have ≥1 cardiometabolic risk factor for COVID-19 complications. Patients will be randomized 1:1 to dapagliflozin 10 mg or placebo. Primary efficacy endpoints are time to development of new or worsened organ dysfunction during index hospitalization, or all-cause mortality, and the hierarchical composite endpoint of change in clinical status through Day 30 of treatment. Safety of dapagliflozin in individuals with COVID-19 will be assessed.
Conclusions: DARE-19 will evaluate whether dapagliflozin can prevent COVID-19-related complications and all-cause mortality, or improve clinical recovery, and assess dapagliflozin's safety profile in this patient population. Currently, DARE-19 is the first large randomized controlled trial investigating use of SGLT2 inhibitors in patients with COVID-19. This article is protected by copyright. All rights reserved.
. 2020 Dec 15.
doi: 10.1111/dom.14296. Online ahead of print.
Effects of Dapagliflozin on Prevention of Major Clinical Events and Recovery in Patients with Respiratory Failure due to COVID-19: The Design and Rationale for the DARE-19 study
Mikhail Kosiborod[SUP] 1 2 [/SUP], Otavio Berwanger[SUP] 3 [/SUP], Gary G Koch[SUP] 4 [/SUP], Felipe Martinez[SUP] 5 [/SUP], Omar Mukhtar[SUP] 6 [/SUP], Subodh Verma[SUP] 7 8 9 [/SUP], Vijay Chopra[SUP] 10 [/SUP], Ali Javaheri[SUP] 11 [/SUP], Philip Ambery[SUP] 12 [/SUP], Samvel B Gasparyan[SUP] 12 [/SUP], Joan Buenconsejo[SUP] 13 [/SUP], C David Sj?str?m[SUP] 12 [/SUP], Anna Maria Langkilde[SUP] 12 [/SUP], Jan Oscarsson[SUP] 12 [/SUP], Russell Esterline[SUP] 13 [/SUP]
Affiliations
- PMID: 33319454
- DOI: 10.1111/dom.14296
Abstract
Aims: Coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated morbidity and mortality, particularly in patients with underlying metabolic, cardiovascular, respiratory, or kidney disease. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has shown significant cardio- and renoprotective benefits in patients with type 2 diabetes (with and without atherosclerotic cardiovascular disease), heart failure, and chronic kidney disease, and may provide similar organ protection in high-risk patients with COVID-19.
Materials and methods: DARE-19 (NCT04350593) is an investigator-initiated, collaborative, international, multicenter, randomized, double-blind, placebo-controlled study testing the dual hypotheses that dapagliflozin can reduce the incidence of cardiovascular, kidney and/or respiratory complications or all-cause mortality, or improve clinical recovery, in adult patients hospitalized with COVID-19 but not critically ill on admission. Eligible patients will have ≥1 cardiometabolic risk factor for COVID-19 complications. Patients will be randomized 1:1 to dapagliflozin 10 mg or placebo. Primary efficacy endpoints are time to development of new or worsened organ dysfunction during index hospitalization, or all-cause mortality, and the hierarchical composite endpoint of change in clinical status through Day 30 of treatment. Safety of dapagliflozin in individuals with COVID-19 will be assessed.
Conclusions: DARE-19 will evaluate whether dapagliflozin can prevent COVID-19-related complications and all-cause mortality, or improve clinical recovery, and assess dapagliflozin's safety profile in this patient population. Currently, DARE-19 is the first large randomized controlled trial investigating use of SGLT2 inhibitors in patients with COVID-19. This article is protected by copyright. All rights reserved.